Protein and lipid biomarkers providing consistent improvement to the prediction of Type 2 diabetes
First Claim
Patent Images
1. A method of treating a subject having an elevated risk for developing a diabetic condition, the method comprising:
- (a) obtaining biomarker measurement data for an individual, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual;
wherein said biomarkers comprise;
(i) glucose, (ii) at least three protein biomarkers selected from the group consisting of;
adiponectin, C-reactive protein, ferritin, glucose, hemoglobin A1c (HbA1c), insulin, and interleukin-2-receptor alpha (IL2RA) and (iii) at least one lipid metabolite selected from the group consisting of;
cholesteryl palmitoleate (CE16;
1n7), cholesteryl homo gamma linoleate (CE20;
3n6), cholesteryl linoleate (CE18;
2n6), cholesteryl palmitate (CE16;
0), cholesteryl petroselinate (CE18;
1n9), 1-linoleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
2n6), and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
1n7 and LY18;
1n9);
(b) identifying the individual as having an elevated risk for developing a diabetic condition based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data; and
(c) treating the individual identified as having an elevated risk for developing a diabetic condition with a treatment regimen to delay or prevent the onset of diabetes.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.
22 Citations
30 Claims
-
1. A method of treating a subject having an elevated risk for developing a diabetic condition, the method comprising:
-
(a) obtaining biomarker measurement data for an individual, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual;
wherein said biomarkers comprise;
(i) glucose, (ii) at least three protein biomarkers selected from the group consisting of;
adiponectin, C-reactive protein, ferritin, glucose, hemoglobin A1c (HbA1c), insulin, and interleukin-2-receptor alpha (IL2RA) and (iii) at least one lipid metabolite selected from the group consisting of;
cholesteryl palmitoleate (CE16;
1n7), cholesteryl homo gamma linoleate (CE20;
3n6), cholesteryl linoleate (CE18;
2n6), cholesteryl palmitate (CE16;
0), cholesteryl petroselinate (CE18;
1n9), 1-linoleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
2n6), and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
1n7 and LY18;
1n9);(b) identifying the individual as having an elevated risk for developing a diabetic condition based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data; and (c) treating the individual identified as having an elevated risk for developing a diabetic condition with a treatment regimen to delay or prevent the onset of diabetes. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 16, 17, 18, 19, 20, 21, 22, 23, 27, 28)
-
-
10. A method of treating an individual at elevated risk for developing a diabetic condition, the method comprising:
-
(a) obtaining measurements of biomarkers from at least one biological sample isolated from the individual, wherein said biomarkers comprise;
(i) glucose, (ii) at least three protein biomarkers selected from the group consisting of;
adiponectin, C-reactive protein, ferritin, glucose, hemoglobin A1c (HbA1c), insulin, and interleukin-2-receptor alpha (IL2RA) and (iii) at least one lipid metabolite selected from the group consisting of;
cholesteryl palmitoleate (CE16;
1n7), cholesteryl homo gamma linoleate (CE20;
3n6), cholesteryl linoleate (CE18;
2n6), cholesteryl palmitate (CE16;
0), cholesteryl petroselinate (CE18;
1n9), 1-linoleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
2n6), and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
1n7 and LY18;
1n9);(b) calculating a risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements of biomarkers, and wherein said model was developed by fitting data from a longitudinal study of a population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals; and (c) initiating a prophylactic regimen to delay or prevent the onset of a diabetic condition in the individual if the calculated risk indicates that the individual has an elevated risk for developing a diabetic condition. - View Dependent Claims (11, 12, 13, 14, 15, 29, 30)
-
-
24. A kit comprising reagents for measuring a group of biomarkers, wherein the biomarkers comprise:
-
(i) glucose, (ii) at least three protein biomarkers selected from the group consisting of;
adiponectin, C-reactive protein, ferritin, glucose, hemoglobin A1c (HbA1c), insulin, and interleukin-2-receptor alpha (IL2RA); and(iii) at least one lipid metabolite selected from the group consisting of;
cholesteryl palmitoleate (CE16;
1n7), cholesteryl homo gamma linoleate (CE20;
3n6), cholesteryl linoleate (CE18;
2n6), cholesteryl palmitate (CE16;
0), cholesteryl petroselinate (CE18;
1n9), 1-linoleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
2n6), and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18;
1n7 and LY18;
1n9). - View Dependent Claims (25, 26)
-
Specification